Eton Pharmaceuticals, Inc. (NASDAQ:ETON – Get Free Report) insider David Krempa sold 25,000 shares of Eton Pharmaceuticals stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $65.07, for a total transaction of $1,626,750.00. Following the transaction, the insider directly owned 37,025 shares of the company’s stock, valued at $2,409,216.75. This represents a 40.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
David Krempa also recently made the following trade(s):
- On Tuesday, May 26th, David Krempa sold 37,524 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $31.49, for a total transaction of $1,181,630.76.
- On Wednesday, May 27th, David Krempa sold 19,679 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $31.47, for a total value of $619,298.13.
Eton Pharmaceuticals Price Performance
Shares of ETON stock traded up $0.96 during trading hours on Monday, hitting $64.43. 801,469 shares of the company’s stock were exchanged, compared to its average volume of 424,905. The stock’s 50-day moving average is $42.16 and its 200-day moving average is $30.34. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.52 and a quick ratio of 1.30. Eton Pharmaceuticals, Inc. has a 52 week low of $14.27 and a 52 week high of $66.37. The stock has a market cap of $1.84 billion, a price-to-earnings ratio of 169.55 and a beta of 0.86.
Hedge Funds Weigh In On Eton Pharmaceuticals
Several hedge funds have recently added to or reduced their stakes in the stock. Sei Investments Co. acquired a new position in Eton Pharmaceuticals during the first quarter valued at approximately $1,432,000. EcoR1 Capital LLC raised its holdings in Eton Pharmaceuticals by 7.0% in the first quarter. EcoR1 Capital LLC now owns 2,171,938 shares of the company’s stock worth $53,603,000 after purchasing an additional 141,394 shares during the period. Walleye Capital LLC acquired a new stake in Eton Pharmaceuticals in the first quarter worth $2,023,000. Wasatch Advisors LP bought a new position in shares of Eton Pharmaceuticals during the second quarter worth $3,357,000. Finally, Aristides Capital LLC grew its holdings in shares of Eton Pharmaceuticals by 15.2% in the 1st quarter. Aristides Capital LLC now owns 186,041 shares of the company’s stock valued at $4,591,000 after buying an additional 24,605 shares during the period. Institutional investors and hedge funds own 27.86% of the company’s stock.
Wall Street Analysts Forecast Growth
Several equities analysts have recently issued reports on the company. HC Wainwright upped their price target on Eton Pharmaceuticals from $65.00 to $70.00 and gave the company a “buy” rating in a research note on Friday, August 14th. Canaccord Genuity Group boosted their price objective on Eton Pharmaceuticals from $60.00 to $68.00 and gave the stock a “buy” rating in a report on Friday, August 14th. Craig Hallum upped their target price on shares of Eton Pharmaceuticals from $40.00 to $62.00 and gave the company a “buy” rating in a research report on Tuesday, July 28th. B. Riley Financial reiterated a “buy” rating and set a $70.00 price target (up from $40.00) on shares of Eton Pharmaceuticals in a research report on Friday, August 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research note on Friday, July 17th. Four equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $67.50.
View Our Latest Report on Eton Pharmaceuticals
About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.
The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.
Further Reading
- Five stocks we like better than Eton Pharmaceuticals
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for Eton Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
